Related Experiment Video
Updated: Aug 3, 2026

Mouse Sperm Cryopreservation and Recovery using the I·Cryo Kit
Published on: December 12, 2011
Sperm cryopreservation for men with nonmalignant, systemic diseases: a descriptive study
Pavithra Ranganathan1, Ayman M Mahran, Jorge Hallak
1Center for Advanced Research in Human Reproduction and Infertility, Urological Institute, The Cleveland Clinic Foundation, Ohio 44195, USA.
Abstract:
Cytotoxic drugs and immunosuppressive therapies are used to treat patients with nonmalignant, nontesticular systemic diseases. These therapies can permanently suppress spermatogenesis. Sperm cryopreservation before treatment theoretically could give these men the opportunity to achieve a pregnancy with a woman later in life when the couple decides to do so. However, it is not known whether pretreatment sperm quality in these men is good enough to be used for assisted reproductive techniques. The main objective of this study was to determine the usefulness of cryopreservation in this patient population by: 1) assessing their pretreatment semen quality (eg, count, motility, and motion kinetics) and comparing it with that of healthy donors before and after cryopreservation; 2) comparing patients' pretreatment semen characteristics with World Health Organization reference values for normal sperm; and 3) examining the differences in semen parameters among patient groups. Semen specimens were obtained from 25 healthy donors and from 23 patients with a variety of disorders (12 had autoimmune disorders, 4 had kidney disorders, 3 had diabetes, 2 had ulcerative colitis, and 2 had heart transplants). All patients, except those with diabetes, required immunosuppressive or cytotoxic therapy. Although the pretreatment quality of the semen of these patients was not as good as that of donors, semen samples were within the normal reference range of the World Health Organization. No statistically significant differences in sperm parameters were found within the 4 patient groups except for those with diabetes (n = 3), who showed poorer sperm counts (P < .04). However, no conclusive evidence can be reached due to the small sample size. Our results indicate that pretreatment semen quality in these patients is adequate for reproductive techniques. We believe that cryopreservation should be offered to patients of reproductive age with disease or treatment regimens that may cause infertility.
Insights
Sperm cryopreservation is a viable option for men with systemic diseases undergoing cytotoxic or immunosuppressive therapy. Pretreatment semen quality is adequate for assisted reproductive techniques, preserving future fertility potential.
Area of Science:
- Reproductive Medicine
- Andrology
- Oncology Supportive Care
Background:
- Cytotoxic and immunosuppressive therapies for nonmalignant systemic diseases can cause permanent infertility by suppressing spermatogenesis.
- Sperm cryopreservation before treatment offers a potential solution for future fertility.
- The suitability of pretreatment sperm for assisted reproductive techniques in this population is uncertain.
Purpose of the Study:
- To assess the pretreatment semen quality of patients undergoing therapies that may impair fertility.
- To compare patient semen quality with healthy donors and World Health Organization (WHO) reference values.
- To evaluate variations in semen parameters among different patient subgroups.
Main Methods:
- Collected semen samples from 23 patients with systemic diseases and 25 healthy donors.
- Analyzed semen parameters including sperm count, motility, and motion kinetics.
- Compared patient data against WHO reference values and donor data before and after cryopreservation.
Main Results:
- Patient pretreatment semen quality was lower than healthy donors but within WHO normal ranges.
- No significant differences in sperm parameters were observed across patient groups, except for lower sperm counts in diabetic patients (n=3).
- Pretreatment semen quality is deemed adequate for assisted reproductive techniques.
Conclusions:
- Sperm cryopreservation should be offered to reproductive-aged men at risk of treatment-induced infertility.
- Pretreatment semen analysis is crucial for assessing fertility preservation options.
- Further research with larger sample sizes is needed to confirm findings in specific patient subgroups.
Related Concept Videos
Spermatogenesis
Infertility in Males

